ATLANTA, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from three ILUVIEN® post marketing studies will be presented during the American Society of Retinal Physicians (ASRS) 2016 Annual Meeting, August 10-14, in San Francisco. In addition, during the meeting Alimera will sponsor two symposia on the treatment of diabetic macular edema.

The studies, to be presented throughout the meeting in the Yerba Buena Ballroom Foyer, Lower B2 Level, are as follows:

  • "To Determine the Efficacy of 0,19 Mg Fluocinolone Acetonide (ILUVIEN®) Intravitreal Implant on Best-Corrected Visual Acuity (BCVA), Central Retinal Thickened (CRT) on Optical Coherence Tomography, and Intraocular Pressure (IOP) in a Cohort of Treatment Experienced Patients with Diabetic Macular Edema (DME)," will be presented as an electronic poster by Jonathan Prenner, M.D., NJ Retina, Brunswick, N.J.
  • "Efficacy Assessment of the 0.2 mg/day Fluocinolone Acetonide (FAc) Intravitreal Implants vs. Sham Control Using the Area Under the Curve (AUC) Method (FAME)," will be presented as an electronic poster by Michael Singer, M.D., Medical Center Ophthalmology Associates, San Antonio, Texas.
  • "Progression of Poliferative Diabetic Retinopathy in Patients treated with 0.2 mg/day Fluocinolone Acetonide for Diabetic Macular Edema --a Fellow-Eye Controlled Study " will be presented as a Paper on Demand by Raymond Iezzi, M.D., Mayo Clinic Department of Ophthalmology, Rochester, Minn.             

On Wednesday, August 10, at 7:15 p.m., Alimera will sponsor a dinner symposium, entitled "Continuous Therapy for DME Patients Requiring Persistent Treatment," hosted by Retinal Physician Magazine in the Foothill G ballroom of the Marriott Marquis. Intended for U.S. Retinal Specialists, the symposium will cover the multifactorial nature of DME, a review of the spectrum of clinical responses for current DME treatments, and a review of continuous therapy for DME to be followed by a discussion of real-world DME cases. Faculty for the event, moderated by Nancy Holekamp, M.D., Pepose Vision Institute, St. Louis, Mo., includes: Vishak John, M.D., Wake Forest Baptist Health, Winston-Salem, N.C., and Daniel Kiernan, M.D., Ophthalmic Consultants of Long Island, N.Y. To register for this symposium, please go to:

 “Individualized Management of Patients with Diabetic Macular Edema,” is a Continuing Medical Education (CME) breakfast symposium, supported by an educational grant from Alimera Sciences, that is slated for Thursday, August 11th, from 6:15 AM to 7:45 AM, in Yerba Buena Salons 1, 2, and 3 at the San Francisco Marriott Marquis. This CME symposium is accredited by the Johns Hopkins University School of Medicine and is part of the Johns Hopkins Advanced Studies in Ophthalmology initiative. The symposium will be directed by Peter A. Campochiaro, M.D. of the Wilmer Eye Institute, Baltimore, Md. The faculty panel includes Nancy M. Holekamp, M.D. from the Washington University School of Medicine in St. Louis and Diana V. Do, M.D. from the University of Nebraska Medical Center in Omaha. The goal of the symposium is to provide retina specialists with the most current clinical knowledge and therapeutic strategies for the optimal treatment and management of patients with DME. To register for this free CME symposium, please go to:     


ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

Alimera Sciences (NASDAQ:ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit


For press inquiries:
Katie Brazel
for Alimera Sciences 

For investor inquiries:
CG Capital
for Alimera Sciences

Primary Logo